FDA 483 - Azico Biophore India Private Limited - September 01, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Azico Biophore India Private Limited, an API manufacturer, revealed significant deficiencies in their cleaning validation processes. The firm failed to adequately evaluate endotoxin contamination for equipment used in manufacturing sterile APIs and did not conduct comprehensive impact assessments for changes to critical cleaning validation procedures. These issues indicate a lack of robust quality control for products intended for sterile finished dosage drug products.
ID · e4424993-a9f7-47d7-8c8d-3360f7a67b79